High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma

Leukemia

Volumn 28, Issue 3, 2014, Pages 719-720

  Kraan, W ^a   Van Keimpema, M ^a   Horlings, H M ^a   Schilder Tol, E J M ^a   Oud, M E C M ^a   Noorduyn, L A ^b   Kluin, P M ^c   Kersten, M J ^a   Spaargaren, M ^a   Pals, S T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Laboratory of Pathology   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD79B ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88;

CLINICAL ARTICLE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LARGE CELL LYMPHOMA; LETTER; MALE; PRIORITY JOURNAL;

ANTIGENS, CD79; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; TESTICULAR NEOPLASMS;

EID: 84895814292     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.348     Document Type: Letter

References (15)

1. Shaffer 3rd Al, Young RM, Staudt LM. The biology of human lymphoid malignancies revealed by gene expression profiling. Ann Rev Immunol 2012; 30: 565-610.
2. Pasqualucci L. The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hemmatol 2013; 20: 336-344.
3. Ahmad SS, Idris SF, Follows GA, Williams MV. Primary testicular lymphoma. Clin Oncol 2012; 24: 358-365.
4. Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial. J Clin Oncol 2011; 29: 2766-2772.
5. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679.
6. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
7. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
8. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
9. Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203-5211.
10. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122: 791-792.
11. Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJM, Oud MECM, Scheepstra C et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immuneprivileged sites. Blood Cancer J 2013; 3: E139.
12. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenströ m's macroglobulinemia. N Engl J Med 2012; 367: 826-833.
13. Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: The other face of lymphocyte homing. Blood 2007; 110: 3102-3111.
14. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-2594.
15. Lim KH, Romero DL, Chaudhary D, Robinson SD, Staudt LM. IRAK4 kinase as a novel therapeutic target in the abc subtype of diffuse large B cell lymphoma. ASH Annual Meeting Abstracts 2012; 120: 62..